NuCana PLC
Change company Symbol lookup
Select an option...
NCNA NuCana PLC
KO Coca-Cola Co
BAC Bank of America Corp
HXL Hexcel Corp
RDHL Redhill Biopharma Ltd
WASH Washington Trust Bancorp Inc
ADC Agree Realty Corp
FB Facebook Inc
HSTM HealthStream Inc
AMZN Amazon.com Inc
Go

Health Care : Biotechnology |
Based in United KingdomCompany profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

Closing Price
$9.10
Day's Change
-0.45 (-4.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.65
Day's Low
9.10
Volume
(Light)
Volume:
1,075

10-day average volume:
10,188
1,075

Display:

Providers:

UpdateCancel
5 providers
July 17, 2019
NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

NUC-7738 is NuCana's Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for...(Globe Newswire)

NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

NUC-7738 is NuCana's Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical...(Thomson Reuters ONE)

June 12, 2019
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin(R) for the Treatment of Biliary Tract Cancer

NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's investigational drug, Acelarin(R) (NUC-1031), for the treatment of biliary tract cancer. Acelarin is a...(Globe Newswire)

NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin(R) for the Treatment of Biliary Tract Cancer

NuCana Remains on Track to Open Global Phase III Study in 2019 EDINBURGH, United Kingdom, June 12, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...(Thomson Reuters ONE)

May 30, 2019
NuCana to Present at the Jefferies 2019 Healthcare Conference

EDINBURGH, United Kingdom, May 30, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies...(Thomson Reuters ONE)

NuCana to Present at the Jefferies 2019 Healthcare Conference

NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 Healthcare Conference in New York, NY. (Globe Newswire)

May 14, 2019
NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2019 and provided an...(Globe Newswire)

NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial...(Thomson Reuters ONE)

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.